Q2 2026 13F · SEC CIK 1056807

Bvf Inc/il

Investment managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $3.9B
Reported positions: 44
Top holdings a year, 3 yrs: +22.3%
Average holding period: 5.2 yrs

Bvf Inc/il is an investment manager that reported 44 positions worth $3.9B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Revolution Medicines Inc (RVMD, 14.2%), Kymera Therapeutics Inc (KYMR, 11.4%), Xoma Royalty Corporation (XOMA, 8.3%). A portfolio copying its top holdings returned 22.3% a year over the last 3 years, against 22.3% for the S&P 500.

Bvf Inc/il holdings all 44 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Bvf Inc/il 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
RVMDRevolution Medicines Inc	14.2%	8.9%	2,965,160	+3.8%	$555.3M
KYMRKymera Therapeutics Inc	11.4%	14.6%	3,872,052	-29.6%	$444.0M
XOMAXoma Royalty Corporation	8.3%	2.6%	7,593,303	+193.1%	$322.7M
MLTXMoonlake Immunotherapeutics	8.0%	9.5%	16,001,284	+0.0%	$311.5M
GHRSGh Research PLC	5.9%	3.9%	8,650,158	+0.0%	$232.5M
GPCRStructure Therapeutics F Unspo	4.6%	5.3%	3,366,823	-2.7%	$180.7M
NKTRNektar Therapeutics	4.3%	5.9%	2,391,075	-6.6%	$166.9M
MIRMMirum Pharmaceuticals Inc	3.2%	4.7%	1,056,027	-33.4%	$123.6M
XNCRXencor Inc	2.9%	2.7%	7,133,720	+0.0%	$114.9M
ALKSAlkermes PLC	2.9%	2.3%	2,154,704	+7.7%	$112.9M
GLUEMonte Rosa Therapeutics Inc	2.8%	2.3%	4,460,886	+0.0%	$108.0M
CGEMCullinan Therapeutics Inc	2.7%	2.6%	5,750,683	+0.0%	$104.7M
PVLAPalvella Therapeutics Inc Ne	2.6%	3.8%	672,789	-30.0%	$102.8M
ZYMEZymeworks Inc	2.4%	3.0%	3,649,142	-2.3%	$95.4M
KURAKura Oncology Inc	2.4%	2.2%	8,445,769	+0.0%	$92.7M
IRONDisc Medicine Inc	2.2%	2.6%	1,153,612	-9.3%	$84.4M
STOKStoke Therapeutics Inc	2.1%	2.6%	2,547,557	+0.0%	$83.4M
OLMAOlema Pharmaceuticals Inc	1.7%	2.5%	5,295,893	+0.0%	$66.3M
ANNXAnnexon Inc	1.3%	1.5%	8,698,173	+0.0%	$49.7M
CBIOCrescent Biopharma Inc	1.3%	1.6%	2,748,763	+0.0%	$49.5M
ACIUAc Immune SA	1.2%	1.7%	19,822,436	+0.0%	$47.2M
TYRATyra Biosciences Inc	1.2%	2.4%	1,476,196	-25.3%	$47.1M
STROSutro Biopharma Inc	1.1%	1.0%	1,251,788	+0.0%	$41.6M
IMCRImmunocore Hldgs PLC	1.1%	1.2%	1,294,463	+0.0%	$41.1M
AVTXAvalo Therapeutics Inc	1.0%	0.8%	2,075,545	+27.1%	$38.4M
FDMT4d Molecular Therapeutics in	1.0%	0.9%	2,879,289	+0.0%	$38.3M
QTTBQ32 Bio Inc	0.8%	New	2,350,000	—	$29.9M
AVRAnteris Technologies Global	0.8%	0.5%	3,000,000	+0.0%	$29.6M
FHTXFoghorn Therapeutics Inc	0.7%	0.9%	5,842,000	+0.0%	$28.5M
ABSIAbsci Corporation	0.7%	New	2,361,674	—	$27.4M
ELDNEledon Pharmaceuticals Inc	0.6%	0.6%	6,293,282	+0.0%	$24.8M
IVVDInvivyd Inc	0.6%	0.8%	28,165,000	+44.3%	$24.6M
SGMTSagimet Biosciences Inc	0.5%	New	2,500,000	—	$19.3M
OKUROnkure Therapeutics Inc	0.4%	0.3%	3,235,778	+63.5%	$14.8M
4525EP200Immunic Inc	0.3%	New	765,295	—	$11.8M
XFORX4 Pharmaceuticals Inc	0.3%	0.3%	2,233,742	+0.0%	$10.4M
IMAImagenebio Inc	0.2%	0.2%	1,110,002	+0.0%	$6.5M
TCRXTscan Therapeutics Inc	0.1%	0.2%	5,564,290	+0.0%	$5.5M
RACCResearch Alliance Corp III	0.1%	New	500,000	—	$5.3M
MOLNMolecular Partners AG	0.1%	0.2%	1,353,968	+0.0%	$5.1M
TENXTenax Therapeutics Inc	0.1%	0.2%	339,549	+0.0%	$4.9M
ENTXEntera Bio Ltd	0.1%	New	2,425,000	—	$4.3M
IVAInventiva SA	0.1%	0.1%	686,040	+0.0%	$2.6M
29286X119Engene Therapeutics Inc	0.0%	New	945,402	—	$274K

What Bvf Inc/il bought and sold in Q2 2026, against Q1 2026.

New positions

QTTB Q32 Bio Inc0.8% of 13F
ABSI Absci Corporation0.7% of 13F
SGMT Sagimet Biosciences Inc0.5% of 13F
Immunic Inc0.3% of 13F
RACC Research Alliance Corp III0.1% of 13F
ENTX Entera Bio Ltd0.1% of 13F
Engene Therapeutics Inc0.0% of 13F

Added to

XOMA Xoma Royalty Corporation+193.1% shares
OKUR Onkure Therapeutics Inc+63.5% shares
IVVD Invivyd Inc+44.3% shares
AVTX Avalo Therapeutics Inc+27.1% shares
ALKS Alkermes PLC+7.7% shares

Reduced

MIRM Mirum Pharmaceuticals Inc-33.4% shares
PVLA Palvella Therapeutics Inc Ne-30.0% shares
KYMR Kymera Therapeutics Inc-29.6% shares
TYRA Tyra Biosciences Inc-25.3% shares
IRON Disc Medicine Inc-9.3% shares
NKTR Nektar Therapeutics-6.6% shares

Sold out

CMPX Compass Therapeutics Incwas 1.3%
SEPN Septerna Incwas 1.0%
Immunic Incwas 0.3%
Engene Holdings Incwas 0.1%

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +57.6% /yr; S&P 500 +11.7%
3 years: +22.3% /yr; S&P 500 +22.3%
5 years: +6.7% /yr; S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$3.9B	44
Q1 2026	$3.1B	41
Q4 2025	$3.0B	41
Q3 2025	$2.5B	46
Q2 2025	$2.8B	44
Q1 2025	$2.5B	51
Q4 2024	$3.0B	53
Q3 2024	$3.4B	55
Q2 2024	$3.6B	60
Q1 2024	$3.6B	62
Q4 2023	$4.0B	70
Q3 2023	$3.7B	69

Questions about Bvf Inc/il's portfolio

What stocks does Bvf Inc/il own?

Bvf Inc/il's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 44 positions worth $3.9B. The largest are Revolution Medicines Inc (RVMD) at 14.2%, Kymera Therapeutics Inc (KYMR) at 11.4%, Xoma Royalty Corporation (XOMA) at 8.3%, Moonlake Immunotherapeutics (MLTX) at 8.0% and Gh Research PLC (GHRS) at 5.9%.

What did Bvf Inc/il buy last quarter?

In Q2 2026, Bvf Inc/il added a new position in Q32 Bio Inc (QTTB), a new position in Absci Corporation (ABSI), a new position in Sagimet Biosciences Inc (SGMT), a new position in Immunic Inc, a new position in Research Alliance Corp III (RACC), Xoma Royalty Corporation (XOMA) (+193.1% shares), Onkure Therapeutics Inc (OKUR) (+63.5% shares) and Invivyd Inc (IVVD) (+44.3% shares), compared with its Q1 2026 filing.

What did Bvf Inc/il sell last quarter?

In Q2 2026, Bvf Inc/il sold all of Compass Therapeutics Inc (CMPX), sold all of Septerna Inc (SEPN), sold all of Immunic Inc, sold all of Engene Holdings Inc, Mirum Pharmaceuticals Inc (MIRM) (-33.4% shares), Palvella Therapeutics Inc Ne (PVLA) (-30.0% shares) and Kymera Therapeutics Inc (KYMR) (-29.6% shares), compared with its Q1 2026 filing.

How has Bvf Inc/il's portfolio performed?

A portfolio copying Bvf Inc/il's 20 largest 13F holdings each quarter, from the day each filing was public, returned +22.3% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +57.6% against +11.7%. Over 5 years: +6.7% a year against +10.6%.

When is Bvf Inc/il's next 13F filing due?

13F filings are due 45 days after each quarter ends. Bvf Inc/il's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.